To elucidate mechanisms underlying CUR’s mitigation of diabetic liver injury, network pharmacology analysis identified AKT1, TNF, TP53, IL-6, and EGFR as top-ranked hub targets against T2DM. Here, TNF is linked to type 2 diabetes mellitus.